HOME >> MEDICINE >> NEWS
AAPS Workshop to Examine Chemistry and Manufacturing Controls Trials, Emerging Products

ALEXANDRIA, Va. -- The American Association of Pharmaceutical Scientists (AAPS) will present the AAPS Workshop on Successful U.S. and EU Registrations: Chemistry and Manufacturing Controls (CMC) Trials and Tribulations, May 3-5, 2000 at the Crystal Gateway Marriott in Arlington, Va.

"This will be a great opportunity for scientists in the pharmaceutical industry and in various government agencies to exchange information on what is working well and what needs to be improved in the CMC area," said Christopher Riley, Ph.D., DuPont Pharmaceuticals. "This unique workshop will give equal time to regulators from Europe and the U.S. and to industrial scientists from the innovator and generic companies."

The workshop will bring together pharmaceutical scientists and regulators from the U.S. and Europe to discuss factors that have resulted in successful drug product registrations from the perspective of Chemistry and Manufacturing Controls. The workshop will also explore what issues have caused problems in this regard, as well as contrasting International Conference on Harmonization (ICH) Quality Guidelines with "total requirements." Topics of focus include drug substances and drug product specifications, test methods and validation, and stability data.

Although there will be formal presentations from the four participating groups (EU, FDA, innovator and generic companies), the main focus of the workshop will be on the break-out groups where participants will have an opportunity to share their experiences and develop recommendations for change.

For more information on this workshop, including a complete preliminary program, registration fees, and accommodations, visit AAPS Online at http://www.aaps.org/edumeet/ tribulations/index.html.

AAPS is a professional, scientific society of more than 10,000 members employed in academia, industry, government and other research institutes worldwid
'"/>

Contact: Debbie Mierke
mierke@aaps.org
703-518-8442
American Association of Pharmaceutical Scientists
12-Apr-2000


Page: 1 2

Related medicine news :

1. Workshop in Kathmandu on space technology for sustainable development in mountain areas
2. TIGER Workshop puts focus on space for African water management
3. Oct. 14 Web cast: Reporters Workshop -- Covering Vaccines & Immunizations
4. AAPS Workshop To Explore Individual Bioequivalence
5. AAPS Announces 1999 Calendar Of Meetings, Conferences And Workshops
6. AAPS Workshop To Address Regulatory Issues
7. Patient Workshop On Trigeminal Neuralgia Scheduled
8. New Book Looks At Those Who Examine Our Sex Lives
9. UK Researchers Receive Grants To Examine Benefits Of Aerobic Exercise For People With Spinal Cord Injuries
10. Analyze This: New Book Examines Shrinks On Screen
11. Heart Valve Abnormalities Examined In Relation To Duration Of Diet Drug Use

Post Your Comments:
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
Cached News: